UPDATE 1-Swiss Alzheimer's biotech AC Immune eyes $700 mln IPO valuation

Sept 14 (Reuters) - AC Immune, the Swiss biotech company

working on treatments for Alzheimer's disease, has set the

pricing band for its keenly awaited U.S. initial public

offering, valuing the firm at about $700 million, at the top end

of the range.

Read more